Mahantesh Sabarad, Deputy VP of Research at SBI Capital Securities told CNBC-TV18, "The most shocking results of the quarter gone by was perhaps, I would say Ranbaxy Laboratories and the pharma sector in general because pharma for the last 5-6 years has never surprised analyst on the downside by such a large extent. Having said that at least the belief with the management is that they will be able to overcome the integration challenges going forward and hence as a stock, as a business Sun Pharmaceutical Industries will continue to see better days ahead."
"The pain is of 3-6 months, we don’t know, so it is very difficult to judge. Having said that, the stock is reflecting merely the uncertainty of the time element in terms of the integration. While the integration will end up positive, we are pretty sure about that, it is just that in interim period people don’t want to take the risk on the stock as yet. For us it is still in a way remains attractive and hence a buy," he said.
Disclosure: Analyst does not own the stocks and he is in the midst of applying for the SEBI regulations and as firm he does not hold these stocks.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
